These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

792 related articles for article (PubMed ID: 28821953)

  • 21. Hypothesis review: Alzheimer's overture guidelines.
    Ferrer I
    Brain Pathol; 2023 Jan; 33(1):e13122. PubMed ID: 36223647
    [TBL] [Abstract][Full Text] [Related]  

  • 22. SUMO and Alzheimer's disease.
    Lee L; Sakurai M; Matsuzaki S; Arancio O; Fraser P
    Neuromolecular Med; 2013 Dec; 15(4):720-36. PubMed ID: 23979993
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Genetically augmenting tau levels does not modulate the onset or progression of Abeta pathology in transgenic mice.
    Oddo S; Caccamo A; Cheng D; Jouleh B; Torp R; LaFerla FM
    J Neurochem; 2007 Aug; 102(4):1053-63. PubMed ID: 17472708
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Spreading of Pathology in Alzheimer's Disease.
    Lv ZY; Tan CC; Yu JT; Tan L
    Neurotox Res; 2017 Nov; 32(4):707-722. PubMed ID: 28623460
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The molecular biology of senile plaques and neurofibrillary tangles in Alzheimer's disease.
    Armstrong RA
    Folia Neuropathol; 2009; 47(4):289-99. PubMed ID: 20054780
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Beta-amyloid sequelae in the eye: a critical review on its diagnostic significance and clinical relevance in Alzheimer's disease.
    Shah TM; Gupta SM; Chatterjee P; Campbell M; Martins RN
    Mol Psychiatry; 2017 Mar; 22(3):353-363. PubMed ID: 28093567
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The difference in gliosis induced by β-amyloid and Tau treatments in astrocyte cultures derived from senescence accelerated and normal mouse strains.
    Lü L; Mak YT; Fang M; Yew DT
    Biogerontology; 2009 Dec; 10(6):695-710. PubMed ID: 19221889
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Progression of Alzheimer's disease, tau propagation, and its modifiable risk factors.
    Takeda S
    Neurosci Res; 2019 Apr; 141():36-42. PubMed ID: 30120962
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Do astrocytes collaborate with neurons in spreading the "infectious" aβ and Tau drivers of Alzheimer's disease?
    Dal Prà I; Chiarini A; Gui L; Chakravarthy B; Pacchiana R; Gardenal E; Whitfield JF; Armato U
    Neuroscientist; 2015 Feb; 21(1):9-29. PubMed ID: 24740577
    [TBL] [Abstract][Full Text] [Related]  

  • 30. A critical analysis of the 'amyloid cascade hypothesis'.
    Armstrong RA
    Folia Neuropathol; 2014; 52(3):211-25. PubMed ID: 25310732
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Origins of Alzheimer's disease: reconciling cerebrospinal fluid biomarker and neuropathology data regarding the temporal sequence of amyloid-beta and tau involvement.
    Musiek ES; Holtzman DM
    Curr Opin Neurol; 2012 Dec; 25(6):715-20. PubMed ID: 23041958
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Amyloid cascade hypothesis: Pathogenesis and therapeutic strategies in Alzheimer's disease.
    Barage SH; Sonawane KD
    Neuropeptides; 2015 Aug; 52():1-18. PubMed ID: 26149638
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Significance of tau in the development of Alzheimer's disease].
    Takashima A
    Brain Nerve; 2010 Jul; 62(7):701-8. PubMed ID: 20675874
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Alzheimer's disease and amyloid: culprit or coincidence?
    Skaper SD
    Int Rev Neurobiol; 2012; 102():277-316. PubMed ID: 22748834
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Twenty Years of Presenilins--Important Proteins in Health and Disease.
    Walter J
    Mol Med; 2015 Oct; 21 Suppl 1(Suppl 1):S41-8. PubMed ID: 26605647
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Expression of apolipoprotein E in Alzheimer's disease and its significance].
    He SR; Liu DG; Wang S; Xia YJ
    Zhonghua Bing Li Xue Za Zhi; 2005 Sep; 34(9):556-60. PubMed ID: 16468304
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The toxicity of tau in Alzheimer disease: turnover, targets and potential therapeutics.
    Pritchard SM; Dolan PJ; Vitkus A; Johnson GV
    J Cell Mol Med; 2011 Aug; 15(8):1621-35. PubMed ID: 21348938
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Transposable elements and Alzheimer's disease pathogenesis.
    Evering TH; Marston JL; Gan L; Nixon DF
    Trends Neurosci; 2023 Mar; 46(3):170-172. PubMed ID: 36588011
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Advanced glycation end products in Alzheimer's disease and other neurodegenerative diseases.
    Sasaki N; Fukatsu R; Tsuzuki K; Hayashi Y; Yoshida T; Fujii N; Koike T; Wakayama I; Yanagihara R; Garruto R; Amano N; Makita Z
    Am J Pathol; 1998 Oct; 153(4):1149-55. PubMed ID: 9777946
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The amyloid hypothesis of Alzheimer's disease: progress and problems on the road to therapeutics.
    Hardy J; Selkoe DJ
    Science; 2002 Jul; 297(5580):353-6. PubMed ID: 12130773
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 40.